Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592260 | 0.84 | UTS2R (0.36) | MEN1KMT2A | |
| SCHEMBL4592262 | 0.84 | UTS2R (0.36) | MEN1KMT2A | |
| SCHEMBL4593086 | 0.83 | NPC1 (0.38) | L3MBTL1NPC1RAB9AKMT2A | |
| SCHEMBL5049233 | 0.82 | CHRNA7 (0.34) | L3MBTL1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4592582 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2A | |
| SCHEMBL4592583 | 0.82 | ALDH1A1 (0.40) | MEN1KMT2A | |
| SCHEMBL4592977 | 0.81 | NPC1 (0.32) | NPC1RAB9A | |
| SCHEMBL4592820 | 0.80 | UTS2R (0.38) | — | |
| SCHEMBL4592817 | 0.80 | UTS2R (0.38) | — | |
| SCHEMBL4592463 | 0.78 | UTS2R (0.37) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | claimed |
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1885691-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006128670-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220003-A1 | C5a Receptor Antagonists | C3AR1, C5AR2, C5AR1 | QPCT 990/4885L3MBTL1 1547/4885MEN1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.